These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38577056)

  • 21. Conjunctivitis in patients with atopic dermatitis treated with dupilumab.
    Ferreira S; Torres T
    Drugs Context; 2020; 9():. PubMed ID: 32426016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis.
    Ou Z; Chen C; Chen A; Yang Y; Zhou W
    Int Immunopharmacol; 2018 Jan; 54():303-310. PubMed ID: 29182975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review.
    Neagu N; Dianzani C; Avallone G; Dell'Aquila C; Morariu SH; Zalaudek I; Conforti C
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):820-835. PubMed ID: 35122335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of dupilumab in a 5-month-old infant with severe atopic dermatitis.
    Havele SA; Khurana MC; McMahon P; Murthy AS; Perman MJ; Treat JR
    Pediatr Dermatol; 2022 Mar; 39(2):291-294. PubMed ID: 35434859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An evaluation of baricitinib as a therapeutic option for adult patients with moderate to severe atopic dermatitis.
    Mendes JT; Balogh EA; Strowd LC; Feldman SR
    Expert Opin Pharmacother; 2020 Jun; 21(9):1027-1033. PubMed ID: 32208940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Profile of dupilumab and its potential in the treatment of inadequately controlled moderate-to-severe atopic dermatitis.
    Awosika O; Kim L; Mazhar M; Rengifo-Pardo M; Ehrlich A
    Clin Cosmet Investig Dermatol; 2018; 11():41-49. PubMed ID: 29416367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials.
    Griffiths C; de Bruin-Weller M; Deleuran M; Fargnoli MC; Staumont-Sallé D; Hong CH; Sánchez-Carazo J; Foley P; Seo SJ; Msihid J; Chen Z; Cyr SL; Rossi AB
    Dermatol Ther (Heidelb); 2021 Aug; 11(4):1357-1372. PubMed ID: 34142350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dupilumab for the Treatment of Atopic Dermatitis.
    Ferreira S; Torres T
    Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):230-240. PubMed ID: 29422431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
    de Bruin-Weller M; Thaçi D; Smith CH; Reich K; Cork MJ; Radin A; Zhang Q; Akinlade B; Gadkari A; Eckert L; Hultsch T; Chen Z; Pirozzi G; Graham NMH; Shumel B
    Br J Dermatol; 2018 May; 178(5):1083-1101. PubMed ID: 29193016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of dupilumab in pediatric patients with moderate to severe atopic dermatitis: a real-world study.
    Yang DY; Li L; Lu T; Jing WW; Liu X; Li XL
    Arch Dermatol Res; 2023 Apr; 315(3):467-472. PubMed ID: 35989340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dupilumab Inhibits Vascular Leakage of Blood Proteins Into Atopic Dermatitis Skin.
    Leung DYM; Bissonnette R; Kreimer S; Berdyshev E; Bafna S; Lyubchenko T; Richers BN; Garcia S; Ramirez-Gama M; Hall CF; Xiao O; Taylor P; Boguniewicz M; Levit NA; Agueusop I; Zhang A; Goleva E
    J Allergy Clin Immunol Pract; 2023 May; 11(5):1421-1428. PubMed ID: 36958520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK.
    O'Kane D; Davis L; Ardern-Jones M; Laws P; Shaw L; Cork M; Velangi S; Cooper HL; Hudson R; Smith AB; Rout R
    Ulster Med J; 2021 May; 90(2):70-76. PubMed ID: 34276083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Psoriasis in dupilumab-treated atopic dermatitis].
    Senner S; Eicher L; Aszodi N; Prinz JC; French LE; Wollenberg A
    Hautarzt; 2020 May; 71(5):383-386. PubMed ID: 32179945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dupilumab in the treatment of moderate-to-severe atopic dermatitis.
    Kraft M; Worm M
    Expert Rev Clin Immunol; 2017 Apr; 13(4):301-310. PubMed ID: 28165826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dupilumab for the treatment of moderate and severe atopic dermatitis: real-life experience.
    Sroka-Tomaszewska J; Bulińska B; Wilkowska A; Nowicki RJ; Trzeciak M
    Postepy Dermatol Alergol; 2023 Dec; 40(6):747-752. PubMed ID: 38282886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.
    Guttman-Yassky E; Bissonnette R; Ungar B; Suárez-Fariñas M; Ardeleanu M; Esaki H; Suprun M; Estrada Y; Xu H; Peng X; Silverberg JI; Menter A; Krueger JG; Zhang R; Chaudhry U; Swanson B; Graham NMH; Pirozzi G; Yancopoulos GD; D Hamilton JD
    J Allergy Clin Immunol; 2019 Jan; 143(1):155-172. PubMed ID: 30194992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab.
    Blauvelt A; Wollenberg A; Eichenfield LF; Zhang H; Sierka D; Khokhar FA; Vakil J; Shabbir A; Marco AR; Cyr SL
    Adv Ther; 2023 Jan; 40(1):367-380. PubMed ID: 36318387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a single-centre, prospective, open-label study.
    Gu C; Wu Y; Luo Y; Wang S; Yin H; Gao Y; Wang C; Yao X; Li W
    J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):1064-1073. PubMed ID: 35344634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children.
    Parker JJ; Sugarman JL; Silverberg NB; Gonzalez ME; Ramien ML; Teng JMC; Paller AS
    Pediatr Dermatol; 2021 Nov; 38(6):1500-1505. PubMed ID: 34647354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dupilumab for atopic dermatitis: evidence to date.
    Rodrigues MA; Nogueira M; Torres T
    G Ital Dermatol Venereol; 2019 Dec; 154(6):696-713. PubMed ID: 31210470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.